Found: 11
Select item for more details and to access through your institution.
Comparative effectiveness of sodium‐glucose co‐transporter‐2 inhibitors and dipeptidyl peptidase‐4 inhibitors on liver function in patients with type 2 diabetes in Japan: A real‐world data analysis.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 3, p. 997, doi. 10.1111/dom.15399
- By:
- Publication type:
- Article
Post hoc analysis of clinical characteristics of patients with radiographic progression in a Japanese phase 3 trial of peficitinib and methotrexate treatment (RAJ4).
- Published in:
- Modern Rheumatology, 2023, v. 33, n. 1, p. 73, doi. 10.1093/mr/roac021
- By:
- Publication type:
- Article
A pooled analysis of serious infections and herpes zoster-related disease in Asian patients with rheumatoid arthritis treated with peficitinib (ASP015K) over a median of 3 years.
- Published in:
- Modern Rheumatology, 2022, v. 32, n. 4, p. 708, doi. 10.1093/mr/roab069
- By:
- Publication type:
- Article
A pooled safety analysis of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis treated over a median of 2 years.
- Published in:
- Modern Rheumatology, 2021, v. 31, n. 3, p. 543, doi. 10.1080/14397595.2020.1836789
- By:
- Publication type:
- Article
Identification and characterization of VopT, a novel ADP-ribosyltransferase effector protein secreted via the Vibrio parahaemolyticus type III secretion system 2.
- Published in:
- Cellular Microbiology, 2007, v. 9, n. 11, p. 2598, doi. 10.1111/j.1462-5822.2007.00980.x
- By:
- Publication type:
- Article
Patient- and physician-reported outcomes from two phase 3 randomized studies (RAJ3 and RAJ4) of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis.
- Published in:
- Arthritis Research & Therapy, 2021, v. 23, n. 1, p. 1, doi. 10.1186/s13075-021-02590-z
- By:
- Publication type:
- Article
Safety and Effectiveness of Peficitinib (ASP015K) in Patients with Rheumatoid Arthritis: Final Results (32 Months of Mean Peficitinib Treatment) From a Long-Term, Open-Label Extension Study in Japan, Korea, and Taiwan.
- Published in:
- Rheumatology & Therapy, 2021, v. 8, n. 1, p. 425, doi. 10.1007/s40744-021-00280-5
- By:
- Publication type:
- Article
Correction to: Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan.
- Published in:
- 2020
- By:
- Publication type:
- Correction Notice
Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan.
- Published in:
- Arthritis Research & Therapy, 2020, v. 22, n. 1, p. 1, doi. 10.1186/s13075-020-2125-2
- By:
- Publication type:
- Article
Healthcare resource utilization and healthcare costs in patients with type 2 diabetes mellitus initiating sodium-glucose cotransporter 2 inhibitors vs dipeptidyl peptidase-4 inhibitors in Japan: A real-world administrative database analysis.
- Published in:
- Journal of Diabetes Investigation, 2024, v. 15, n. 3, p. 374, doi. 10.1111/jdi.14123
- By:
- Publication type:
- Article
Cardiometabolic risk reductions in patients with type 2 diabetes mellitus newly treated with a sodium–glucose cotransporter 2 inhibitor versus a dipeptidyl peptidase‐4 inhibitor: A real‐world administrative database study in Japan
- Published in:
- Journal of Diabetes Investigation, 2023, v. 14, n. 3, p. 404, doi. 10.1111/jdi.13952
- By:
- Publication type:
- Article